Anaptysbio Announces Strategic Antibody Discovery Partnership with Celgene
News Apr 12, 2012
AnaptysBio, Inc. has announced a strategic partnership with Celgene Corporation to develop novel antibodies against multiple therapeutic targets.
Under this partnership, AnaptysBio is responsible for generating novel therapeutic antibodies to oncology and inflammation-related targets using its proprietary SHM-XEL platform.
Celgene will receive worldwide rights to develop and commercialize antibodies discovered by AnaptysBio under the terms of the partnership.
In addition to an upfront payment, AnaptysBio is due to receive preclinical and clinical milestone payments from Celgene, as well as royalties upon sales of each product derived from the partnership.
“AnaptysBio is uniquely positioned with a state-of-the-art antibody platform and an experienced antibody development team,” said Hamza Suria, AnaptysBio’s president and chief executive officer.
Suria continued, “We look forward to advancing novel antibody therapeutics with Celgene, in parallel with our internal pipeline programs.”
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019